Search

Purpose: To evaluate the presence of macular edema secondary to retinal vein occlusion (RVO)-both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO)-3 years after diagnosis in patients who underwent intravitreal therapy and to identify potential prognostic factors and biomarkers of persistent macular edema., Methods: National multicenter, observational, exploratory, retrospective cohort study of 104 consecutive patients with macular edema secondary to RVO diagnosed from January 2014 to December 2015 with minimum 3-year follow-up time. Data analyzed included best-corrected visual acuity (BCVA), clinical and demographic data, and spectral domain optical coherence tomography parameters., Results: At final observation, median baseline central retinal thickness significantly improved from baseline 538 to 290 μm (p < 0.001) and complete macular edema resolution was achieved in 51.0% of patients (56.3% and 42.5% in BRVO and CRVO patients, respectively). BCVA also improved (p < 0.01). Logistic regression analysis revealed a relationship between recurrence of macular edema and disorganization of retinal inner layers (DRIL) at baseline (odds ratio = 2.88; p = 0.013)., Conclusion: Good long-term anatomical and functional outcomes are achieved with intravitreal treatments in RVO patients. Anatomical success and visual gains seen in the first year were maintained throughout the entire follow-up, though DRIL is a major risk factor for recurrence.

Purpose: To evaluate the presence of macular edema secondary to retinal vein occlusion (RVO)—both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO)—3 years after diagnosis in patients who underwent intravitreal therapy and to identify potential prognostic factors and biomarkers of persistent macular edema. Methods: National multicenter, observational, exploratory, retrospective cohort study of 104 consecutive patients with macular edema secondary to RVO diagnosed from January 2014 to December 2015 with minimum 3-year follow-up time. Data analyzed included best-corrected visual acuity (BCVA), clinical and demographic data, and spectral domain optical coherence tomography parameters. Results: At final observation, median baseline central retinal thickness significantly improved from baseline 538 to 290 μm (p < 0.001) and complete macular edema resolution was achieved in 51.0% of patients (56.3% and 42.5% in BRVO and CRVO patients, respectively). BCVA also improved (p < 0.01). Logistic regression analysis revealed a relationship between recurrence of macular edema and disorganization of retinal inner layers (DRIL) at baseline (odds ratio = 2.88; p = 0.013). Conclusion: Good long-term anatomical and functional outcomes are achieved with intravitreal treatments in RVO patients. Anatomical success and visual gains seen in the first year were maintained throughout the entire follow-up, though DRIL is a major risk factor for recurrence. [ABSTRACT FROM AUTHOR]

Purpose: To determine whether the disorganization of retinal inner layers (DRIL) on spectral-domain (SD) OCT is associated with visual outcomes in eyes with treatment-naive branch retinal vein occlusion (BRVO). Materials and Methods: Thirty-two eyes of 32 treatment-naive patients with macular edema (ME) due to BRVO receiving three initial consecutive monthly intravitreal ranibizumab were enrolled in this study. SD-OCT images from baseline, 3rd-month, 6th-month visits were observed and the presence and extent of DRIL was examined in the central 1-mm-wide foveal area. The efficacy of the ranibizumab treatment, assessed by best-corrected visual acuity (BCVA), was evaluated at baseline, 3-month and 6-month visits. Results: A total of 32 eyes were included and DRIL was present in 14 (43.7%) eyes at baseline and 9 eyes (28.1%) at 6th month (P:0.01). Baseline DRIL was found to be associated with lower baseline BCVA (0.46 LogMAR for without DRIL vs. 0.65 LogMAR for DRIL, P: 0.013) and higher central retinal thickness (405.7 vs. 442.8, P: 0.016). Decrease in DRIL intensity at 3-month follow-up was associated with increased visual acuity (VA) at 6 months (P:0.001) and baseline DRIL extent was a predictive parameter for 6 months improvement in VA (p:0.01). Sixmonth DRIL change was related to 6-month VA improvement (Pearson's correlation test, r=0.726, P<0.001). Conclusion: In the present study, it was observed that the improvement of BCVA was found to be related to the decrease of the DRIL intensity. Therefore, the presence of DRIL at baseline and extent of DRIL following treatment might serve as a potential SD-OCT biomarker for patients with ME secondary to treatment-naive-BRVO. [ABSTRACT FROM AUTHOR]

Purpose: To determine the predictive values of baseline optical coherence tomography (OCT) abnormalities on 12-month visual acuity changes in eyes with macular edema (ME) caused by branch retinal vein occlusions (BRVO).Methods: We performed a post hoc analysis of data from 75 participants in the 12-month MARVEL trial. OCT abnormalities at baseline, including ganglion cell layer cystoid spaces (GCL), intraretinal hyper-reflective dots, and central subfield thickness (CST), were correlated with improvements in visual acuity and the number of anti-vascular endothelial growth factor injections required using a multivariate regression model.Results: Eyes with baseline CST > 500 μm had greater visual gains compared to those with CST <500 μm (+21.09 vs +16.08 letters, P = 0.04). Eyes with hyper-reflective dots (+13.97 vs +19.93 letters, P = 0.02), and GCL cysts (+9.8 vs +18.9, P = 0.003) had inferior gains in visual acuity. Neurosensory macular detachments at the baseline did not affect gains in visual acuity. Ninety percent of the gain in visual acuity was recorded after two injections and was maintained until month 12.Conclusion: Baseline OCT of <500 μm, hyper-reflective dots, and GCL cystoid spaces are associated with poorer gains in visual acuity. Most of the visual gain occurs after two injections. [ABSTRACT FROM AUTHOR]